NOTICIA
30/6/2026Resumen IA
Royalty Pharma Opens Hong Kong Office Amid Rising Chinese Biotech Deals and US Investment Restrictions
Royalty Pharma, the world's largest biopharmaceutical royalty buyer, established its first Asia-Pacific base in Hong Kong. This move aims to capitalize on record Chinese biotech out-licensing deals and offers an alternative financing method amidst US investment restrictions and geopolitical uncertainties.
S
SCMP Tech1 min de lectura